Weighing Coronary Revascularization Options in Patients With Type 2 Diabetes Mellitus

Lucas C Godoy1, Caio A M Tavares2, Michael E Farkouh3

  • 1Peter Munk Cardiac Centre, University of Toronto, Toronto, Ontario, Canada; Heart and Stroke/Richard Lewar Centres of Excellence in Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada; Instituto do Coracao, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

Insights

Patients with diabetes mellitus and coronary artery disease often benefit from coronary artery bypass grafting over percutaneous coronary intervention for stable multivessel disease. Lifestyle changes are crucial post-revascularization for managing cardiovascular disease risk factors.

Area of Science:

  • Cardiology
  • Diabetology
  • Vascular Medicine

Background:

  • Patients with diabetes mellitus (DM) have a higher risk of coronary artery disease (CAD).
  • Optimal revascularization strategy selection (coronary artery bypass grafting vs. percutaneous coronary intervention) is challenging in this population.
  • Evidence suggests coronary artery bypass grafting is generally superior to percutaneous coronary intervention for stable multivessel disease in patients with DM.

Purpose of the Study:

  • To review current literature on managing patients with DM and CAD undergoing revascularization.
  • To discuss the comparative effectiveness of different revascularization strategies in diabetic patients.
  • To highlight the importance of risk factor management post-revascularization.

Main Methods:

  • Literature review of current evidence.
  • Analysis of studies comparing coronary artery bypass grafting and percutaneous coronary intervention in diabetic patients with CAD.
  • Synthesis of findings regarding revascularization outcomes and post-procedure management.

Main Results:

  • Coronary artery bypass grafting is typically superior to percutaneous coronary intervention for stable multivessel ischemic heart disease in patients with DM, showing lower long-term mortality, myocardial infarction, and repeat revascularization rates.
  • Percutaneous coronary intervention may be a viable option for less complex coronary anatomy (e.g., single- or two-vessel disease without proximal left anterior descending artery involvement).
  • Evidence is limited for patients with DM and left main disease or those presenting with acute coronary syndromes.

Conclusions:

  • Coronary artery bypass grafting is generally preferred for stable multivessel CAD in diabetic patients.
  • Percutaneous coronary intervention can be considered for select cases with less complex disease.
  • Aggressive risk factor control (smoking cessation, lipid, blood pressure, glycemic management, diet, exercise) is essential after revascularization to prevent cardiovascular disease progression.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
200
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
210
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
828
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
557
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
287